PLx Pharma Issues Statement On Recent USPTF Recommendations On Asprin Therapy For Primary Prevention Of Cardiovascular Disease
PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide
12 Health Care Stocks Moving In Wednesday’s After-Market Session
Gainers
TransCode Therapeutics (NASDAQ:RNAZ) shares increased by 5.4% to $2.73 during Wednesday's after-market session. The company's market cap stands at $35.2 million.
BWS Financial Initiates Coverage On PLx Pharma with Buy Rating, Announces Price Target of $29
BWS Financial analyst Hamed Khorsand initiates coverage on PLx Pharma (NASDAQ:PLXP) with a Buy rating and announces Price Target of $29.
PLx Pharma’s VAZALORE Now on Shelves; National Media Campaign Launches Today
PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide
PLx Pharma Shares Move Higher; Traders Circulate Amazon Listing Showing Co’s Main Product Vazalore Has Been Added To Site
https://www.amazon.com/VAZALORETM-Aspirin-Immediate-Liquid-Filled-Capsules/dp/B09C2TDW92/
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)
PLx Pharma Q2 Adj. EPS $(0.28) Misses $(0.22) Estimate
PLx Pharma (NASDAQ:PLXP) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.22) by 27.27 percent. This is a 37.78 percent increase over losses of $(0.45) per share from the